Sorry, you need to enable JavaScript to visit this website.

Greenstone LLC Introduces MONTELUKAST Sodium Tablets and Chewable Tablets Generic of SINGULAIR®

PEAPACK, N.J., August 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Montelukast Sodium Tablets and Chewable Tablets to its ever-expanding generic pharmaceutical product line. The tablets are offered in dosage strengths of 10 mg and the chewable tablets are offered in dosage strengths of 4 mg and 5 mg.

Greenstone's Montelukast product is the generic of and bioequivalent to SINGULAIR® (montelukast) Tablets. This new generic complements Greenstone's line of generic products, and is backed by a commitment to integrity, quality, and supply reliability. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality medicines to customers, payers, and the patients they serve.

See the Full Prescribing Information, including Boxed Warning, for Greenstone’s Montelukast Sodium Tablets and Chewable Tablets at http://www.greenstonellc.com/product-list.aspx. For more information about Greenstone LLC and its products, visit http://greenstonellc.com.